CVS Health Corporation reflects attractive technical aspects that could allow investors to expect a trend reversal over the medium term. Investors should benefit from the breakout of the $ 66 level to target the $ 70.62.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
In a short-term perspective, the company has interesting fundamentals.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Historically, the company has been releasing figures that are above expectations.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.53 for the 2020 fiscal year.
With a P/E ratio at 11.45 for the current year and 10.73 for next year, earnings multiples are highly attractive compared with competitors.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.